See you in Shanghai! HitGen Pharmaceuticals Inc. to attend the 5th China International Import Expo Release Time：2022-11-03

The 5th China International Import Expo (CIIE) will be held at the National Exhibition and Convention Center (Shanghai) from on November 5-10, 2022.

CIIE is the first national-level import-themed professional trade fair in the world. It connects the Chinese and global markets, and shows China's drive to further open up to the world in the new era. Since its debut, the CIIE’s role has become more notable as a major platform for international procurement, investment promotion, cultural exchanges, and open cooperation. With continuously expanding spillover effect, CIIE provides ample business opportunities for enterprises both at home and abroad. 

HitGen Pharmaceuticals Inc., a wholly-owned subsidiary of HitGen Inc., will attend this year’s CIIE to showcase its cutting-edge technologies and solutions in advancing innovative drug discovery. We look forward to meeting you at Booth NHD-2 in Innovation Incubation Special Section (North Hall, NH)!

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com

For business development: bd@hitgen.com